Ipsen And Genfit Announced Topline Data From The Pivotal ELATIVE Phase 3 Trial, Of Elafibrano For Primary Biliary Cholangitis; The Trial Met Its Primary Composite Endpoint, With 51% Of Patients Achieving Cholestasis Response Compared With 4% On Placebo
Portfolio Pulse from Benzinga Newsdesk
Ipsen and Genfit have announced topline data from the pivotal ELATIVE Phase 3 trial of Elafibrano for Primary Biliary Cholangitis. The trial met its primary composite endpoint, with 51% of patients achieving cholestasis response compared with 4% on placebo.
June 30, 2023 | 10:18 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genfit's Elafibrano met its primary endpoint in a Phase 3 trial, potentially leading to regulatory approval and increased revenues.
Positive trial results often lead to regulatory approval, which can increase revenues and positively impact the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Ipsen's Elafibrano met its primary endpoint in a Phase 3 trial, potentially leading to regulatory approval and increased revenues.
Positive trial results often lead to regulatory approval, which can increase revenues and positively impact the stock price.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 50